Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.
To help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome, Thermo Fisher Scientific Inc. is partnering with NCI on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.
Arsenal Biosciences Inc. advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T-cell therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher’s Cell Therapy Systems portfolio of products, including the Gibco CTS Xenon Electroporation System and the Gibco CTS Rotea Counterflow Centrifugation System.
Thermo Fisher Scientific and AstraZeneca formed a global, multiyear agreement to develop a solid tissue and blood-based companion diagnostic test for Tagrisso (osimertinib).
Thermo Fisher Scientific is accepting submissions for the fifth round of the Oncomine Clinical Research Grant program.
Thermo Fisher Scientific has launched a next-generation sequencing-based assay for research in myeloid measurable residual disease.
Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated next-generation sequencing platform that delivers results in as soon as 24 hours.
Thermo Fisher Scientific is calling for proposals for its Oncomine Clinical Research Grant. The latest request for submissions will award funding for molecular profiling research that helps accelerate the use of genomic sequencing in oncology.
